Contact
searchSearch
HMP Global
Login
Test Your Knowledge

Quiz: Are EGFR-TKIs Viable With Chemo in Advanced NSCLC?

01/31/2022

Related Content

Joshua Sabari, MD; Julia Rotow, MD; Estelamari Rodriguez, MD, MPH
Videos
Round 3: Establishing the Frontline Standard
11/02/2026
Estelamari Rodriguez, MD, MPH; Joshua Sabari, MD; Julia Rotow, MD
In the final round, faculty consider a fit patient with relatively limited metastatic disease, exploring where osimertinib monotherapy may remain appropriate and how efficacy, tolerability, patient preferences, and treatment burden inform the...
In the final round, faculty consider a fit patient with relatively limited metastatic disease, exploring where osimertinib monotherapy may remain appropriate and how efficacy, tolerability, patient preferences, and treatment burden inform the...
In the final round, faculty...
11/02/2026
Oncology
Joshua Sabari, MD; Julia Rotow, MD; Estelamari Rodriguez, MD, MPH
Videos
Round 2: Managing Frontline Brain Metastases
11/02/2026
Estelamari Rodriguez, MD, MPH; Joshua Sabari, MD; Julia Rotow, MD
The discussion turns to a patient with small, asymptomatic brain metastases and additional high-risk features. Faculty examine how CNS efficacy data, molecular characteristics, and the potential role of CNS-directed therapy influence...
The discussion turns to a patient with small, asymptomatic brain metastases and additional high-risk features. Faculty examine how CNS efficacy data, molecular characteristics, and the potential role of CNS-directed therapy influence...
The discussion turns to a...
11/02/2026
Oncology
Joshua Sabari, MD; Julia Rotow, MD; Estelamari Rodriguez, MD, MPH
Videos
Frontline Treatment Selection in EGFR-Mutated Metastatic NSCLC
11/02/2026
Estelamari Rodriguez, MD, MPH; Joshua Sabari, MD; Julia Rotow, MD
Thoracic oncology experts debate frontline treatment strategies for patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC). Through three patient cases, faculty explore when to intensify treatment upfront, where osimertinib...
Thoracic oncology experts debate frontline treatment strategies for patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC). Through three patient cases, faculty explore when to intensify treatment upfront, where osimertinib...
Thoracic oncology experts debate...
11/02/2026
Oncology
WCLC Early-Stage
Conference Coverage
WCLC 2026 Highlights: Evolving Strategies in Early-Stage EGFR+ NSCLC
10/30/2026
Sarah Goldberg, MD, MPH; Jamie Chaft, MD; Edward B. Garon, MD, MS; Eric K. Singhi, MD
In this expert panel, faculty examine emerging WCLC 2026 data in EGFR+ NSCLC across early-stage disease. The discussion explores the clinical implications of new evidence for treatment selection while considering study limitations and...
In this expert panel, faculty examine emerging WCLC 2026 data in EGFR+ NSCLC across early-stage disease. The discussion explores the clinical implications of new evidence for treatment selection while considering study limitations and...
In this expert panel, faculty...
10/30/2026
Oncology

Recent News

News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology
News
SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results...
11/04/2026
Oncology
News
Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1...
11/04/2026
Oncology
News
Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors
11/04/2026
Emily Estrada
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial...
11/04/2026
Oncology
FDA Alerts
Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results
11/04/2026
Stephanie Holland
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3...
11/04/2026
Oncology
News
Medicare Expands Coverage of Signatera MRD Testing for Hepatocellular Carcinoma Surveillance
11/03/2026
Stephanie Holland
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been...
11/03/2026
Oncology
News
What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium
11/02/2026
Janelle Bradley
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS...
11/02/2026
Oncology
News
Phase 3 IMpactMF Trial of Imetelstat Discontinued After Unfavorable Overall Survival Assessment
10/30/2026
Emily Estrada
The phase 3 IMpactMF trial of imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis has been discontinued after an independent Data Monitoring Committee determined that the study was unlikely to meet its primary...
The phase 3 IMpactMF trial of imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis has been discontinued after an independent Data Monitoring Committee determined that the study was unlikely to meet its primary...
The phase 3 IMpactMF trial of...
10/30/2026
Oncology
News
Cosibelimab Receives NCCN Category 2A Recommendation for Locally Advanced Cutaneous Squamous Cell Carcinoma
10/30/2026
Emily Estrada
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include...
10/30/2026
Oncology
News
Petosemtamab Plus Pembrolizumab Significantly Improves Overall Survival in Patients With Head and Neck Squamous Cell Carcinoma
10/30/2026
Emily Estrada
Results from the phase 3 LiGeR-HN1 trial demonstrated that petosemtamab plus pembrolizumab significantly improved overall survival and objective response compared with pembrolizumab alone in patients with PD-L1-positive recurrent or...
Results from the phase 3 LiGeR-HN1 trial demonstrated that petosemtamab plus pembrolizumab significantly improved overall survival and objective response compared with pembrolizumab alone in patients with PD-L1-positive recurrent or...
Results from the phase 3...
10/30/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use